Chemistry:AGN-241751
From HandWiki
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Drug class | NMDA receptor modulator |
| Identifiers | |
| CAS Number | |
AGN-241751 is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD).[1][2] It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018.[1][2] Allergan (previously Naurex) is also developing the NMDA receptor modulators rapastinel (GLYX-13; intravenous) and apimostinel (NRX-1074, AGN-241660; oral) for the treatment of MDD.[3][4][5] Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel.[2][6] As of May 2018, the drug is in phase I clinical trials.[1][2]
See also
References
- ↑ 1.0 1.1 1.2 "Research programme: NMDA receptor modulators - Allergan - AdisInsight". https://adisinsight.springer.com/drugs/800031388.
- ↑ 2.0 2.1 2.2 2.3 Inc., Aptinyx. "Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration". https://www.prnewswire.com/news-releases/allergan-exercises-option-to-acquire-compound-from-aptinyx-discovery-platform-under-ongoing-research-collaboration-300652397.html.
- ↑ "Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics". CNS Neurol Disord Drug Targets 16 (8): 858–869. 2018. doi:10.2174/1871527316666170728165648. PMID 28758582.
- ↑ "Rapastinel - Allergan - AdisInsight". https://adisinsight.springer.com/drugs/800031281.
- ↑ "Apimostinel - Allergan - AdisInsight". https://adisinsight.springer.com/drugs/800038114.
- ↑ "J&J therapy for suicidal depressives 'a breakthrough', says FDA". 17 August 2016. http://www.pmlive.com/pharma_news/j_and_j_therapy_for_suicidal_depressives_a_breakthrough,_says_fda_1101990.
External links
 |
